Specifically, the expression and upregulation of GPR158 has been linked to tumour progression and unfavourable survival in prostate cancer and gliomas, but the literature is otherwise limited with regard to targeted GPR158 therapy [66,90]. Here, GPR158 is linked to central nervous system cancer.